Ocuphire Pharma EBITDA Margin 2010-2024 | IRD
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Ocuphire Pharma (IRD) over the last 10 years. The current EBITDA margin for Ocuphire Pharma as of June 30, 2024 is .
| Ocuphire Pharma EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-06-30 |
$0.02B |
$-0.02B |
-88.24% |
| 2024-03-31 |
$0.02B |
$-0.01B |
-60.00% |
| 2023-12-31 |
$0.02B |
$-0.01B |
-50.00% |
| 2010-06-30 |
$0.00B |
$-0.01B |
inf% |
| 2010-03-31 |
$0.00B |
$-0.01B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
